Wechselwirkungen · Cresemba
CRESEMBA 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 10–11
HOS-128921 · Präparat HOS-096645
(CYP3A4/5 induction) Indinavir Indinavir:b) No isavuconazole dose (CYP3A4/5 strong inhibitor AUCinf: ↓ 36% adjustment necessary; caution is and substrate) Cmax: ↓ 52% 10 advised as adverse drug reactions (Mechanism unknown) may increase. Indinavir: careful monitoring for Isavuconazole concentrations may any occurrence of lack of anti- increase. viral efficacy, and dose increase if required. (CYP3A4/5 inhibition) Saquinavir Not studied. No isavuconazole dose (strong CYP3A4 inhibitor) Saquinavir concentrations may adjustment necessary; caution is decrease (as observed with advised as adverse drug reactions lopinavir/ritonavir) or increase. may increase. Saquinavir: careful monitoring (CYP3A4 inhibition) for any occurrence of drug toxicity and /or lack of anti-viral Isavuconazole concentrations may efficacy, and dose adjustment if increase. required
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) saquinavir (HOS-084522) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage a4b92271ed7bccf2acde3f6efe9e831fc9dc71a3158444cfe16bac6cb41c7670 · Zeichen 17954–19751 im Abschnitt